Mural Oncology PLC (MURA) Company Sales

Corporate emblem and logo of Mural Oncology PLC (MURA)

Mural Oncology plc (MURA) is optimizing costs by utilizing external CDMO facilities for drug production. The company's absolute sales confirm the effectiveness of this strategy, where the current metric equals 0.00. The development of an immune-activating cytokine system provides targeted tumor therapy. Thanks to an autonomous product cycle, the business remains a defensive asset against macroeconomic shocks, maintaining stable demand for its innovations.

muraloncology.com (MURA): Company Revenue from 02/21/2024 to 12/20/2025

Analytical breakdowns for Mural Oncology plc

- market price and analyst price targets:
General company analysis:Mural Oncology PLC - MURA
Core merchandise of Mural Bio

The indicator is calculated as the sum of all daily product sales receipts, reflecting the business's actual cash flow. This metric allows for the identification of hidden operational degradation, where an asset's external cheapness masks falling revenues. For Mural Oncology plc (MURA), revenue growth confirms the commercialization of their precision immunotherapeutic developments against tumors. By analyzing the company's sales dynamics, an investor can assess the sustainability of market demand for innovative drugs.

Analysis of competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Total Revenue|OSTX: Company Sales|Company Sales Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Revenue|ANL: Company Total Sales|VERU (Veru Corporation) - Revenue and Sales Volume|Company Total Revenue Tempest Therapeutics, Inc. TPST|Revenue and Sales Volume XLO|Renovaro - Company Sales Volume|Revenue and Sales Volume KAPA (kairospharma.com)|Company Gross Revenue OnKure (OKUR)|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue